Indaptus Therapeutics, Inc. (INDP)
2025-06-30 | ||||
|---|---|---|---|---|
| Other income, net | 15,547 | |||
| Research and development | 2,167,114 | |||
| General and administrative | 2,289,649 | |||
| Total operating expenses | 4,456,763 | |||
| Loss from operations | -4,456,763 | |||
| Change in fair value of convertible promissory notes | -787,703 | |||
| Net loss | -5,228,919 | |||
| Net loss available to common stockholders per share of common stock, basic | -9.09 | |||
| Net loss available to common stockholders per share of common stock, diluted | -9.09 | |||
| Weighted average number of shares used in calculating net loss per share, basic | 574,923 | |||
| Weighted average number of shares used in calculating net loss per share, diluted | 574,923 | |||